INM InMed: התחייבויות שוטפות של החברה

InMed Pharmaceuticals (INM) has optimized production by outsourcing synthesis to third-party partners while maintaining control over its unique yeast strains. The business is independent of economic cycles or seasonality, relying instead on scientific progress, as reflected in the price chart on GURU.Markets, where the metric stands at 0.00. InMed Pharmaceuticals (INM) has earned trust as a developer of innovative therapies for skin and vision organs.

This indicator aggregates all financial obligations of InMed Pharmaceuticals (INM) maturing within one year, allowing for an assessment of current liquidity and default risk. By analyzing the volume of short-term debt capital, an investor determines the biopharmaceutical company's ability to fund laboratory research without emergency fundraising, taking into account the issuer's minimal expenditures on environmental infrastructure.